GlassScriptPhysician profile
Vinay Patel
NPI 1013048016
$10,272.75
in general payments reported to CMS, 2019-2025
40 companies · $2,151 in 2025
The $2,151 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $578 · 2020: $493 · 2021: $2,079 · 2022: $1,701 · 2023: $1,456 · 2024: $1,815 · 2025: $2,151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,391 · Education: $30.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,390.87 |
| Education | $30.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,375.42 | 2019-2025 | |
| Janssen Biotech, INC. | $1,091.48 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Boston Scientific Corporation | $901.76 | 2021-2025 | General - Biliary Devices, Watchman Access System, Exalt Model D |
| Takeda Pharmaceuticals U.S.A., INC. | $850.89 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $821.70 | 2019-2025 | Xifaxan, Trulance |
| Gilead Sciences, INC. | $530.59 | 2019-2025 | |
| Pfizer INC. | $449.76 | 2019-2025 | |
| Qol Medical, LLC | $356.58 | 2019-2025 | Sucraid |
| Ironwood Pharmaceuticals, INC | $274.78 | 2019-2024 | Linzess |
| Regeneron Healthcare Solutions, INC. | $208.05 | 2022-2025 | Dupixent |
| Amgen INC. | $203.43 | 2020-2023 | Avsola, Amjevita |
| Aimmune Therapeutics, INC. | $199.25 | 2024-2025 | Zenpep |
| Genzyme Corporation | $193.63 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $172.06 | 2024-2025 | Voquezna |
| Daiichi Sankyo INC. | $169.23 | 2022 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $146.65 | 2019-2023 | Ocaliva |
| Nestle Healthcare Nutrition INC. | $120.45 | 2021-2023 | |
| Lilly USA, LLC | $118.29 | 2023-2025 | Omvoh |
| Ferring Pharmaceuticals INC. | $113.78 | 2021-2024 | Rebyota |
| Merck Sharp & Dohme LLC | $112.73 | 2020-2024 | Dificid |
| Celgene Corporation | $99.05 | 2021-2023 | Zeposia |
| Madrigal Pharmaceuticals | $93.71 | 2024-2025 | Rezdiffra, Resmetirom |
| Intra-Sana Laboratories | $87.47 | 2021-2022 | |
| Braintree Laboratories, INC. | $84.50 | 2019-2024 | Suflave, Sutab |
| Ethicon INC. | $72.90 | 2022-2023 | Monarch Platform |
| Celltrion USA INC. | $57.39 | 2024-2025 | Vegzelma, Zymfentra |
| Organon LLC | $42.62 | 2023-2025 | Hadlima |
| Fresenius Kabi USA, LLC | $40.79 | 2023 | Idacio |
| Evoke Pharma, INC. | $39.88 | 2022-2025 | |
| Alnylam Pharmaceuticals INC. | $35.22 | 2020-2025 | Givlaari |
| Novo Nordisk INC | $32.59 | 2023-2025 | Wegovy |
| Ardelyx, INC. | $30.36 | 2023-2025 | Ibsrela |
| Blueprint Medicines Corporation | $27.26 | 2023 | |
| Conmed Corporation | $26.41 | 2020 | |
| W. L. Gore & Associates, INC. | $25.95 | 2021-2022 | |
| Ethicon US, LLC | $19.62 | 2020 | |
| Shire North American Group INC | $19.13 | 2019 | |
| Ambu INC. | $13.95 | 2020 | |
| Redhill Biopharma INC. | $13.44 | 2023 | Talicia |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vinay Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.